We are live on ! Find out more
XDNA

Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA

Delisted

XDNA was delisted on the 30th of November, 2023.

Back to rankings

2 hedge funds and large institutions have $279K invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

82% less capital invested

Capital invested by funds: $1.54M → $279K (-$1.26M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$1.19M
2
Citadel Advisors
Citadel Advisors
Florida
-$16.3K
3
UBS Group
UBS Group
Switzerland
-$1.86K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
1
Citadel Advisors
Florida
$226K -$16.3K -1,455 -6%
UBS Group
2
UBS Group
Switzerland
$53.2K -$1.86K -166 -3%
Jane Street
3
Jane Street
New York
– -$1.19M -101,588 Closed

XDNA Hedge Fund Activity: Q4 2022 in Review

2 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q4 2022, worth a combined $279K — down 82% from $1.54M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of XDNA and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest seller was Jane Street, exiting entirely with an estimated $1.19M sold.

  • 2 institutional investors held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q4 2022, down from 3 in Q3 2022.
  • Funds reported $279K of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q4 2022, down 82% quarter-over-quarter.
  • 0 funds opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q4 2022 and 1 closed out, a net change of -1 holder.
  • The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF seller in Q4 2022 was Jane Street, an estimated $1.19M sold.

Based on aggregated 13F filings for Q4 2022.